ADH-associated pathologies.
Diabetes insipidus and syndrome of inappropriate ADH The last time you enjoyed those hot dogs and potatoOne of the hormones involved is antidiuretic hormone (ADH). Like all hormones, ADH profoundly affects some life-sustaining functions
Adherex Presents Final Clinical Data on ADH-1 Phase 1 Trial at ASCO Annual Meeting.
Fla. -- Adherex Technologies Inc. (AMEX:ADH)(TSX:AHX), a biopharmaceutical company withthe molecularly targeted anti-cancer drug ADH-1 (Exherin(TM)) today at the 2005 Americana major international cancer conference. ADH-1 targets N-cadherin, a protein present
Adherex Initiates Clinical Trial Program for ADH-1 in Combination With Chemotherapy; Study to Explore ADH-1 in Combination With Docetaxel,......
Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broadannounced the initiation of a Phase I trial of ADH-1 in combination with chemotherapy in conjunctionUS Oncology's Chief Scientific Officer. ADH-1's molecular target, N-cadherin, is a novel
Adherex Announces Two Presentations of ADH-1 Data at 2007 American Association of Cancer Research Annual Meeting.
Adherex Technologies Inc. (TSX:AHX) (AMEX:ADH), a biopharmaceutical company with a broadCompany will be presenting preclinical data on ADH-1 in combination with chemotherapy in aentitled Synergistic anti-tumor activity of ADH-1 in vitro and in vivo in combination with
Adherex and National Cancer Institute to Collaborate on Clinical Development of ADH-1 'Exherin 'TM''.
N.C. -- Adherex Technologies Inc. (AMEX:ADH)(TSX:AHX), a biopharmaceutical company withthe Company's lead biotechnology compound ADH-1, also known as Exherin(TM), provided additionalexisting preclinical and clinical data on ADH-1. As part of the collaboration, the NCI
Adherex to Present ADH-1 and Eniluracil Data at 2007 ASCO Meeting.(Clinical report)
Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broadthat Phase II clinical data on single-agent ADH-1 and preclinical and preliminary Phasestudy of the N-cadherin (N-cad) antagonist ADH-1 in subjects with N-cadherin expressing
Data From Adherex's European Phase Ib/II Trial of ADH-1 to be Presented at International Symposium on Targeted Anticancer Therapies....
Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broadEuropean Phase Ib/II study of single-agent ADH-1, will present data today from that studyaggregate of over 200 doses (68 cycles) of ADH-1 given on a weekly schedule with doses
Adherex Presents Phase Ib Data From European ADH-1 Trial at ASCO 2006 Annual Meeting: ADH-1 was well tolerated and showed additional......
Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broadthe molecularly targeted anti-cancer drug, ADH-1, which is being presented at the 2006an aggregate of 123 doses (41 cycles) of ADH-1 given on a weekly schedule with doses
Adherex to Present Data at Rodman & Renshaw Conference Indicating Broad Presence of ADH-1 Target on Multiple Cancers.
Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broaddata relevant to the market potential of ADH-1 (Exherin(TM)) during its presentationcancers expressed N-cadherin, the target for ADH-1, and thus may be susceptible to ADH-1
ADH HEALTH PRODUCTS INC.
COMPANY DESCRIPTION ADH Health Products specializes in custom formulationscutting-edge technology. For more than 18 years, ADH has been a leading manufacturer of all-naturalThe variety of supplements produced by ADH meet the growing demands of those who insist
|
|
|
ADH-associated pathologies.